Boehringer Ingelheim · 8 hours ago
Senior Principal Scientist, Portfolio In silico Evidence Lead, Computational Biology
Boehringer Ingelheim is seeking a highly motivated and accomplished Senior Principal Scientist to drive in silico evidence generation and advance novel therapeutic candidates. This pivotal role will be instrumental in advancing understanding of disease mechanisms and driving drug discovery efforts for new dermatological and rheumatological indications.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Drive the generation of robust in silico evidence packages to support the progression of NTCs through critical development milestones
Lead and execute bioinformatics projects to deliver innovative NTC MoA insights, with a particular emphasis on dermatological applications
Leverage single and spatial omics technologies, machine learning/AI techniques, biological knowledge, and deep disease understanding to build compelling in silico evidence packages
Contribute to clinical biomarker discovery efforts and/or data-driven safety and toxicity assessments
Work closely with colleagues in I&R, as well as in vitro and in vivo biologists, to integrate computational findings with experimental data
Develop and implement novel omics-based computational approaches to address key challenges in drug development
Apply computational expertise to various stages of the drug development pipeline, from target identification to late-stage clinical development
Qualification
Required
Ph.D. in Bioinformatics, Computational Biology, Immunology, Molecular Biology, or a related discipline with 7 or more years of relevant post-doctoral and/or industry experience in drug discovery and development, with at least three (3) years of experience in drug discovery
Demonstrated expertise in understanding complex disease mechanisms, particularly within immunology, dermatology, and/or rheumatology
Expertise in bioinformatics, including the analysis of large-scale biological datasets (e.g., single-cell RNA-seq, spatial transcriptomics, genomics, proteomics)
Proficiency in machine learning and artificial intelligence techniques for biological data analysis
Strong understanding of immunology and disease mechanisms, particularly in the context of dermatology and rheumatology
Experience collaborating with experimental biologists (in vitro and in vivo) to design experiments and interpret results
Demonstrated ability to translate complex computational findings into clear and actionable insights for drug development teams
Excellent communication, interpersonal, and presentation skills
Proven ability to work independently and as part of a highly collaborative, multidisciplinary team
Provides expert-level scientific and bioinformatics expertise within the area(s) of biology and human disease addressed by the TA
Knowledge of current key datasets, therapeutic landscape and demographic/epidemiological considerations within TA is required
Must be legally authorized to work in the United States without restriction
Must be willing to take a drug test and post-offer physical (if required)
Must be 18 years of age or older
Preferred
Experience with clinical biomarker discovery or data-driven safety & toxicity assessment
Familiarity with regulatory requirements and guidelines in drug development
Prior experience in dermatology and rheumatology research
Benefits
Role specific variable or performance-based bonus
Other compensation elements
Company
Boehringer Ingelheim
Boehringer Ingelheim is a group of pharmaceutical companies that focuses on prescription medicines and animal health. It is a sub-organization of Boehringer Ingelheim.
H1B Sponsorship
Boehringer Ingelheim has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (4)
2023 (11)
2022 (7)
2021 (17)
2020 (1)
Funding
Current Stage
Late StageLeadership Team
Recent News
Company data provided by crunchbase